Coronary artery bypass surgery hormonal manipulation: Difference between revisions

Jump to navigation Jump to search
VisualWikitext
(Blanked the page)
No edit summary
Line 1: Line 1:
__NOTOC__
[[Coronary artery bypass surgery]]
{{CMG}}


==2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)<ref name="pmid22064599">{{cite journal| author=Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG et al.| title=2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. | journal=Circulation | year= 2011 | volume=  | issue=  | pages=  | pmid=22064599 | doi=10.1161/CIR.0b013e31823c074e | pmc= | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22064599  }} </ref>==
===Coronary artery bypass surgery hormonal manipulation===
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LightGreen"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class I]]
|-
| bgcolor="LightGreen"|<nowiki>"</nowiki>'''1.''' Use of continuous intravenous [[insulin]] to achieve and maintain an early postoperative blood glucose concentration less than or equal to 180 mg/dL while avoiding [[hypoglycemia]] is indicated to reduce the incidence of adverse events, including deep sternal wound infection, after CABG  ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|}
{|class="wikitable"
|-
|colspan="1" style="text-align:center; background:LightCoral"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class III: HARM]]
|-
|bgcolor="LightCoral"|<nowiki>"</nowiki>'''1.''' Postmenopausalhormonaltherapy([[estrogen]]/[[prosgesterone]])shouldnot be administered to women undergoing CABG ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
{|class="wikitable"
|-
| colspan="1" style="text-align:center; background:LemonChiffon"|[[ACC AHA guidelines classification scheme#Classification of Recommendations|Class IIb]]
|-
|bgcolor="LemonChiffon"|<nowiki>"</nowiki>'''1.''' The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness ''([[ACC AHA guidelines classification scheme#Level of Evidence|Level of Evidence: B]])''<nowiki>"</nowiki>
|}

Revision as of 17:24, 1 November 2016

Coronary artery bypass surgery Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery (DO NOT EDIT)[1]

Coronary artery bypass surgery hormonal manipulation

Class I
"1. Use of continuous intravenous insulin to achieve and maintain an early postoperative blood glucose concentration less than or equal to 180 mg/dL while avoiding hypoglycemia is indicated to reduce the incidence of adverse events, including deep sternal wound infection, after CABG (Level of Evidence: B)"
Class III: HARM
"1. Postmenopausalhormonaltherapy(estrogen/prosgesterone)shouldnot be administered to women undergoing CABG (Level of Evidence: B)"
Class IIb
"1. The use of continuous intravenous insulin designed to achieve a target intraoperative blood glucose concentration less than 140 mg/dL has uncertain effectiveness (Level of Evidence: B)"
  1. ↑ Hillis LD, Smith PK, Anderson JL, Bittl JA, Bridges CR, Byrne JG; et al. (2011). "2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines". Circulation. doi:10.1161/CIR.0b013e31823c074e. PMID 22064599.
Retrieved from "https://www.wikidoc.org/index.php?title=Coronary_artery_bypass_surgery_hormonal_manipulation&oldid=1265936"